Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies

Trial Profile

Phase 1b Multi-indication Study of Anetumab Ravtansine (BAY94-9343) in Patients With Mesothelin Expressing Advanced or Recurrent Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2017

At a glance

  • Drugs Anetumab ravtansine (Primary) ; Cisplatin; Gemcitabine
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ARCS-Multi
  • Sponsors Bayer
  • Most Recent Events

    • 15 Oct 2017 Trial design presented at the 18th World Conference on Lung Cancer.
    • 12 Sep 2017 Trial design of the study presented at the 42nd European Society for Medical Oncology Congress.
    • 01 Sep 2017 According to a Bayer media release, data from this trial will be presented at the European Society for Medical Oncology (ESMO) Congress in Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top